Miraculins Inc (MCUIF) 0.1800 $MCUIF Luminor Me
Post# of 273333
Posted On: 09/16/2016 3:02:29 AM
Miraculins Inc (MCUIF) 0.1800 $MCUIF
Luminor Medical Announces Equity Financing, Convertible Debt Financing and Shares for Debt Transaction
ACCESSWIRE - Fri Sep 02, 1:41PM CDT
MONTREAL, QC / ACCESSWIRE / September 2, 2016 / Luminor Medical Technologies Inc. (TSXV: LMT) (the "Company" or "Luminor Medical"
(formerly Miraculins Inc.) announces it plans to complete a non-brokered financing of up to 4,000,000 units (each a "Unit" at a price of $0.15 per Unit to raise gross proceeds of up to $600,000. Each Unit will consist of one common share and one half of one common share purchase warrant (a "Warrant" with each Warrant exercisable at a price of $0.25 for a period of two years. The proceeds will be used for general working capital purposes.
LMT.VN: 0.270 (-0.015)
Miraculins Announces Name Change, New Stock Symbol and Share Consolidation
ACCESSWIRE - Wed Apr 13, 7:09AM CDT
WINNIPEG, MB / ACCESSWIRE / April 13, 2016 / Miraculins Inc. (TSXV: MOM) (the "Company" announces that it has changed its name to Luminor Medical Technologies Inc. and will commence trading on the TSX Venture Exchange under the new symbol "LMT" at the open of market on April 14, 2016. As previously announced on March 22, 2016, the Company has also completed a twenty-five to one (25 - 1) consolidation of its common shares resulting in the Company having approximately 2,020,656 common shares issued and outstanding as of April 14, 2016.
MOM.VN: 0.010 (unch)
Miraculins Appoints Ashwath Mehra to the Board of Directors
ACCESSWIRE - Tue Feb 09, 6:18AM CST
WINNIPEG, MB / ACCESSWIRE / February 9, 2016 / Miraculins Inc. (TSXV: MOM) (the "Company", a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs announces today, the appointment of Mr. Ashwath Mehra to the Company's Board of Directors.
MOM.VN: 0.010 (unch)
Miraculins Announces the Appointment of Chris Carmichael as Chief Financial Officer
ACCESSWIRE - Mon Jan 18, 7:11AM CST
WINNIPEG, MB / ACCESSWIRE / January 18, 2016 / Miraculins Inc. (TSXV: MOM) (the "Company", a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs announces that effective today, Mr. Christopher Carmichael, CPA, CGA, has been appointed Chief Financial Officer (CFO) of the Company. Mr. Carmichael replaces Mr. James Kinley, who has served as CFO since December 23, 2011 under a management services agreement between the Company and Genesys Venture Inc., which recently expired. The appointment of Mr. Carmichael is subject to regulatory approval.
MOM.VN: 0.010 (unch), GDE-A.VN: 0.340 (-0.060)
Diabetes Health Costs Surpass GDP of Norway; Miraculins Launches Non-Invasive Diabetes Screen
ACCESSWIRE - Tue Feb 10, 8:05AM CST
VANCOUVER, BC / ACCESSWIRE / February 10, 2015 / According to the World Health Organisation, diabetes affects 400 million people world-wide, resulting in five million deaths per year while consuming $540 billion in health-related expenses.
Miraculins Moves Closer to Commercialization
ACCESSWIRE - Mon Feb 09, 7:01AM CST
WHITEFISH, MT / ACCESSWIRE / February 9, 2015 / Diabetes is the seventh leading cause of death in the United States with over a million new cases each year, according to the American Diabetes Association, costing the healthcare system $176 billion in direct costs and the economy $76 billion in lost productivity in 2012.
PODD: 42.17 (+0.93), DXCM: 92.75 (+0.96), NVO: 46.24 (+0.19), MOM.VN: 0.010 (unch), LLY: 78.82 (+0.53)
Miraculins: Pioneering a New Approach to Diabetes Screening
ACCESSWIRE - Tue Jan 27, 7:03AM CST
WINNIPEG, CA / ACCESSWIRE / January 27, 2015 / Diabetes affects nearly 30 million U.S. citizens - or roughly 10% of the population - with about 27% of those cases going undiagnosed, according to the American Diabetes Association. As well, there are approximately 80 million Americans estimated to be pre-diabetic, with 90% being completely unaware of their condition. With about 70,000 deaths in 2010 alone, diabetes is the seventh leading cause of death in the U.S. and that figure could be dramatically understated given the chronic under-diagnosis of the disease. [1] As well, diabetes and its related complications accounted for $245 billion USD in total medical costs and lost work and wages in the U.S. in 2012.[2] More than 500 million people worldwide are expected to be affected by diabetes by the year 2030, making it the 7th leading cause of death in the world. [3] [4]
MOM.VN: 0.010 (unch)
Luminor Medical Announces Equity Financing, Convertible Debt Financing and Shares for Debt Transaction
ACCESSWIRE - Fri Sep 02, 1:41PM CDT
MONTREAL, QC / ACCESSWIRE / September 2, 2016 / Luminor Medical Technologies Inc. (TSXV: LMT) (the "Company" or "Luminor Medical"
(formerly Miraculins Inc.) announces it plans to complete a non-brokered financing of up to 4,000,000 units (each a "Unit" at a price of $0.15 per Unit to raise gross proceeds of up to $600,000. Each Unit will consist of one common share and one half of one common share purchase warrant (a "Warrant" with each Warrant exercisable at a price of $0.25 for a period of two years. The proceeds will be used for general working capital purposes. LMT.VN: 0.270 (-0.015)
Miraculins Announces Name Change, New Stock Symbol and Share Consolidation
ACCESSWIRE - Wed Apr 13, 7:09AM CDT
WINNIPEG, MB / ACCESSWIRE / April 13, 2016 / Miraculins Inc. (TSXV: MOM) (the "Company"
announces that it has changed its name to Luminor Medical Technologies Inc. and will commence trading on the TSX Venture Exchange under the new symbol "LMT" at the open of market on April 14, 2016. As previously announced on March 22, 2016, the Company has also completed a twenty-five to one (25 - 1) consolidation of its common shares resulting in the Company having approximately 2,020,656 common shares issued and outstanding as of April 14, 2016. MOM.VN: 0.010 (unch)
Miraculins Appoints Ashwath Mehra to the Board of Directors
ACCESSWIRE - Tue Feb 09, 6:18AM CST
WINNIPEG, MB / ACCESSWIRE / February 9, 2016 / Miraculins Inc. (TSXV: MOM) (the "Company"
, a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs announces today, the appointment of Mr. Ashwath Mehra to the Company's Board of Directors. MOM.VN: 0.010 (unch)
Miraculins Announces the Appointment of Chris Carmichael as Chief Financial Officer
ACCESSWIRE - Mon Jan 18, 7:11AM CST
WINNIPEG, MB / ACCESSWIRE / January 18, 2016 / Miraculins Inc. (TSXV: MOM) (the "Company"
, a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs announces that effective today, Mr. Christopher Carmichael, CPA, CGA, has been appointed Chief Financial Officer (CFO) of the Company. Mr. Carmichael replaces Mr. James Kinley, who has served as CFO since December 23, 2011 under a management services agreement between the Company and Genesys Venture Inc., which recently expired. The appointment of Mr. Carmichael is subject to regulatory approval. MOM.VN: 0.010 (unch), GDE-A.VN: 0.340 (-0.060)
Diabetes Health Costs Surpass GDP of Norway; Miraculins Launches Non-Invasive Diabetes Screen
ACCESSWIRE - Tue Feb 10, 8:05AM CST
VANCOUVER, BC / ACCESSWIRE / February 10, 2015 / According to the World Health Organisation, diabetes affects 400 million people world-wide, resulting in five million deaths per year while consuming $540 billion in health-related expenses.
Miraculins Moves Closer to Commercialization
ACCESSWIRE - Mon Feb 09, 7:01AM CST
WHITEFISH, MT / ACCESSWIRE / February 9, 2015 / Diabetes is the seventh leading cause of death in the United States with over a million new cases each year, according to the American Diabetes Association, costing the healthcare system $176 billion in direct costs and the economy $76 billion in lost productivity in 2012.
PODD: 42.17 (+0.93), DXCM: 92.75 (+0.96), NVO: 46.24 (+0.19), MOM.VN: 0.010 (unch), LLY: 78.82 (+0.53)
Miraculins: Pioneering a New Approach to Diabetes Screening
ACCESSWIRE - Tue Jan 27, 7:03AM CST
WINNIPEG, CA / ACCESSWIRE / January 27, 2015 / Diabetes affects nearly 30 million U.S. citizens - or roughly 10% of the population - with about 27% of those cases going undiagnosed, according to the American Diabetes Association. As well, there are approximately 80 million Americans estimated to be pre-diabetic, with 90% being completely unaware of their condition. With about 70,000 deaths in 2010 alone, diabetes is the seventh leading cause of death in the U.S. and that figure could be dramatically understated given the chronic under-diagnosis of the disease. [1] As well, diabetes and its related complications accounted for $245 billion USD in total medical costs and lost work and wages in the U.S. in 2012.[2] More than 500 million people worldwide are expected to be affected by diabetes by the year 2030, making it the 7th leading cause of death in the world. [3] [4]
MOM.VN: 0.010 (unch)
(0)
(0)